Atlas Trials

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

Clinical trial NCT03398655 · COMPLETED

Trial details

NCT number
NCT03398655
Sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Recurrent Platinum Resistant Ovarian Cancer
Start date
2017-12-19
Primary completion
2022-07-19
Enrollment
408

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.